Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. [electronic resource]
Producer: 20141215Description: 402-10 p. digitalISSN:- 1365-2141
- Adolescent
- Allografts
- Central Nervous System Neoplasms -- therapy
- Child, Preschool
- Epstein-Barr Virus Infections -- immunology
- Female
- HLA Antigens -- analysis
- Herpesvirus 4, Human -- immunology
- Histocompatibility Testing
- Humans
- Immunotherapy, Adoptive
- Infant
- Leiomyosarcoma -- therapy
- Licensure
- Lung Neoplasms -- therapy
- Lymphoproliferative Disorders -- etiology
- Male
- Middle Aged
- New Zealand
- Postoperative Complications -- immunology
- Remission Induction
- Sarcoma -- therapy
- T-Cell Antigen Receptor Specificity
- T-Lymphocytes, Cytotoxic -- immunology
- Tissue Banks -- organization & administration
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.